Kilitch Drugs (India) Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 344.31 million compared to INR 203.27 million a year ago. Revenue was INR 357.4 million compared to INR 206.96 million a year ago. Net income was INR 11.25 million compared to INR 22.15 million a year ago. Basic earnings per share from continuing operations was INR 0.72 compared to INR 1.43 a year ago. Diluted earnings per share from continuing operations was INR 0.72 compared to INR 1.43 a year ago.
For the nine months, sales was INR 776.27 million compared to INR 485.91 million a year ago. Revenue was INR 801.58 million compared to INR 497.51 million a year ago. Net income was INR 44.69 million compared to INR 29.63 million a year ago. Basic earnings per share from continuing operations was INR 2.87 compared to INR 1.91 a year ago. Diluted earnings per share from continuing operations was INR 2.87 compared to INR 1.91 a year ago.